Zura Bio Limited (NASDAQ:ZURA) Receives $14.00 Average PT from Analysts

Key Points

• Zura Bio Limited (NASDAQ:ZURA) has received an average rating of "Buy" from analysts, with one hold rating, six buy ratings, and one strong buy rating.
• The average target price for Zura Bio stock among brokerages is set at $14.00, despite recent target price reductions by some analysts.
• Institutional investors hold 61.14% of Zura Bio's stock, with several hedge funds increasing their stakes significantly in recent months.

Zura Bio Limited (NASDAQ:ZURA - Get Free Report) has received a consensus recommendation of "Buy" from the eight analysts that are currently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation, six have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $14.00.

A number of equities analysts have recently issued reports on the company. HC Wainwright cut their price objective on Zura Bio from $3.00 to $2.00 and set a "neutral" rating for the company in a report on Tuesday, August 19th. Oppenheimer lowered their price objective on shares of Zura Bio from $17.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, August 15th. Finally, Chardan Capital reiterated a "buy" rating and issued a $10.00 target price on shares of Zura Bio in a research report on Friday, August 15th.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently modified their holdings of ZURA. Two Sigma Advisers LP purchased a new stake in Zura Bio in the fourth quarter worth about $32,000. Savant Capital LLC grew its stake in shares of Zura Bio by 190.4% in the 2nd quarter. Savant Capital LLC now owns 32,409 shares of the company's stock worth $34,000 after buying an additional 21,249 shares during the last quarter. ProShare Advisors LLC bought a new position in Zura Bio during the 4th quarter valued at approximately $35,000. Wells Fargo & Company MN raised its stake in Zura Bio by 68.6% during the fourth quarter. Wells Fargo & Company MN now owns 23,053 shares of the company's stock valued at $58,000 after buying an additional 9,379 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in Zura Bio during the fourth quarter valued at $62,000. 61.14% of the stock is owned by hedge funds and other institutional investors.

Zura Bio Trading Down 1.0%

Shares of NASDAQ:ZURA traded down $0.02 during mid-day trading on Monday, reaching $2.02. The company had a trading volume of 160,363 shares, compared to its average volume of 358,078. Zura Bio has a one year low of $0.97 and a one year high of $5.07. The company's 50-day moving average price is $1.56 and its 200-day moving average price is $1.35. The firm has a market cap of $131.34 million, a price-to-earnings ratio of -2.89 and a beta of -0.02.

Zura Bio (NASDAQ:ZURA - Get Free Report) last announced its quarterly earnings data on Thursday, August 14th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.02. On average, research analysts anticipate that Zura Bio will post -0.65 EPS for the current fiscal year.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.